Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform
Stock Information for Abeona Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.